AU research team awarded $4.4 million American Heart Association grant

Jun 25, 2025

5 min

Jennifer Sullivan, PhDMarlo Vernon, PhD

A research team at Augusta University, led by Jennifer C. Sullivan, PhD, has secured a $4.4 million grant from the American Heart Association to study the risk factors for cardiovascular and kidney diseases and how they impact women.


Sullivan’s research center, “Disruptions in cardiorenal free fatty acid metabolism in Cardiovascular Kidney Metabolic Syndrome,” is part of a larger $15 million project titled “Strategically Focused Research Network on Cardiovascular Kidney Metabolic Syndrome: Heterogeneity in Women.” The overarching AHA project is aimed at learning why women may be more likely to develop cardiovascular and kidney diseases due to certain unique risk factors and life stages. Research teams from Massachusetts General Hospital and The Ohio State University were also chosen.



“I think this is a huge step for Augusta University as we continue to distinguish ourselves and the research that we have here focused on the health of women,” said Sullivan, dean of The Graduate School. “This grant is particularly impactful as we look to advance and improve the health of women, not just in Georgia, but for the entire country.”


According to the Healthy Georgia Report, produced by AU’s School of Public Health, Georgia has the 23rd highest rate of obesity in the United States. Among the women living in the state, 38.3% of them, as well as 37.5% of people living in rural areas, suffer from obesity.







“It’s great that we are able to represent the state of Georgia because our state has such a high prevalence for obesity rates,” said Sullivan, who is the director of AU’s SCORE project “Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk).” “It’s important for us to understand that different populations have distinct needs. You can’t talk about a one-size-fits-all approach to health. This is really about trying to understand how different groups are impacted.”



Each center is comprised of three teams, as well as a training component and an area partner. Together, they will explore obesity’s lifetime impact on CKM syndrome through three projects.


CKM syndrome is a clinical term that describes the combined health effects of heart disease, kidney disease, diabetes and obesity, which puts people at high risk for heart attack, stroke and heart failure. According to the American Heart Association’s 2025 Heart Disease and Stroke Statistics, about 1 in 3 U.S. adults has at least three components of CKM syndrome, which include high blood pressure, abnormal cholesterol, high blood glucose (sugar), impaired kidney function and excess body weight.


The first project is led by Daria Ilatovskaya, PhD, and Justine Abais-Battad, PhD, and will look at aging and Western diet-induced CKMS mechanisms in obesity. Ilatovskaya is an associate professor and the graduate program director for the Doctor of Philosophy in Physiology program, and Abais-Battad is an assistant professor in the Department of Physiology with the Medical College of Georgia at Augusta University.


The second component, led by Jessica Faulkner, PhD, an assistant professor in MCG’s Physiology department, will study obesity-associated mechanisms of CKMS in pregnancy.


The third project, led by Stephen Coughlin, PhD, with Marlo Vernon, PhD, is looking at CKMS epidemiology, associations with obesity, CVD/CKD. Coughlin is the program director for the Master of Science in Epidemiology and professor of epidemiology in the School of Public Health’s Department of Biostatistics, Data Science, and Epidemiology, while Vernon is an associate professor with MCG’s Georgia Prevention Institute and SPH’s Department of Community and Behavioral Health Sciences.


Additionally, the team will talk to women and health care providers from a variety of backgrounds and experiences to assess current knowledge and interest levels in heart health and use that information to develop programs that may help treat and prevent disease.


There is also a training director, Alison Kriegel, PhD, a professor in the Department of Physiology, and a core director, Guido Verbeck, PhD, chair and professor of the Department of Chemistry and Biochemistry in the College of Science and Mathematics.


“We have a strong blend of clinical epidemiology and basic science, as well as a training component, which we will fill with post-doctoral fellows,” Sullivan said. “Dr. Ilatovskaya, Dr. Faulkner, Dr. Abais-Battad and Dr. Vernon are all a part of our ROAR grant, and, while this isn’t directly related to that program, it allowed us to demonstrate how we are already well positioned to work together to amplify our ability and increase awareness about the importance of the health of women.”


The team has over 50 collaborative papers and has secured more than $13 million in collaborative funding to advance the health of women. They also all have experience training fellows and students to continue to expand their reach.




“We already have a lot of the infrastructure in place for this kind of cross-disciplinary project, so we leaned very heavily into our connections and the expertise we have here at Augusta University. It’s set up very similar to our ROAR program, so this is something that was really organic in nature,” Sullivan said.


The American Heart Association has invested almost $300 million to establish 18 Strategically Focused Research Networks, each aimed at addressing a key strategic issue identified by the association’s volunteer Board of Directors. Prior networks have been studying a wide variety of important topics including, but not limited to, prevention, hypertension, the health of women, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias/sudden cardiac death, cardiometabolic health/type 2 diabetes, health technology, cardio-oncology, the biological impact of chronic psychosocial stress and the role of inflammation in cardiovascular health.


Each network centers around scientific knowledge and knowledge gaps, prevention, diagnosis and treatment of the key research topic. Three to six research centers make up each network, bringing together investigators with expertise in basic, clinical and population/behavioral health science to find new ways to diagnose, treat and prevent heart disease and stroke.


Funding scientific research and discovery through initiatives like these awards is a cornerstone of the century-old American Heart Association’s lifesaving mission. The association has now funded more than $5.9 billion in cardiovascular, cerebrovascular and brain health research since 1949, making it the single largest non-government supporter of heart and brain health research in the United States. New knowledge resulting from this funding continues to save lives and directly impact millions of people in every corner of the U.S. and around the world.



Looking to know more about the amazing research happening at Augusta?


To connect with Dr. Sullivan, simply click on her icon to arrange an interview today.


Connect with:
Jennifer Sullivan, PhD

Jennifer Sullivan, PhD

Interim Provost and Dean of The Graduate School

Jennifer Sullivan, PhD, is an internationally recognized expert of sex differences in cardiovascular physiology and pathophysiology.

HypertensionCardiovascular PhysiologyPathophysiology Higher Education Administration
Marlo Vernon, PhD

Marlo Vernon, PhD

Associate Professor, Department of Community and Behavioral Health Sciences, School of Public Health

Skilled in Program Evaluation, Grant Writing, Program Development, Public Health Research and Data Analysis.

Physical ActivityChildhood ObesityProgram DevelopmentProgram EvaluationPublic Health Research

You might also like...

Check out some other posts from Augusta University

2 min

Fueling the Future of Cancer Immunotherapy: Gang Zhou’s Research Takes a Major Step Forward

Cancer immunotherapy has transformed how clinicians approach the treatment of certain blood cancers, but major limitations remain — especially when it comes to sustaining strong, long-lasting immune responses. Gang Zhou, PhD, a leading cancer immunologist at Augusta University’s Georgia Cancer Center and the Immunology Center of Georgia, is tackling these challenges head-on. Zhou’s work focuses on how T cells behave inside the body and how their performance can be enhanced to improve patient outcomes. His lab studies the forces that strengthen or weaken T cell responses, including their functional status, their ability to self-renew and the environmental pressures they face inside tumors. This deep understanding positions him as a key figure in the effort to advance next-generation immunotherapies. Recently, Zhou and his research team were awarded the first Ignite Grant from the Immunology Center of Georgia — a seed program designed to support bold, high-impact translational ideas. Their funded project aims to make CAR-T therapy more effective. CAR-T is a type of immunotherapy in which a patient’s own T cells are genetically modified to recognize and attack cancer cells. While this approach has revolutionized the treatment of certain blood cancers, it still faces obstacles such as limited cell persistence and reduced strength over time. “Our ultimate goal is to engineer T cells that not only survive longer but also remain highly functional, giving patients more durable protection against their disease.” Zhou’s team is addressing this issue by studying how a modified form of STAT5, a transcription factor that plays a key role in T cell survival and function, may help engineered T cells last longer and perform better. The ultimate goal is to create CAR-T therapies that maintain potency, withstand the harsh tumor microenvironment, and offer durable results for patients. The Ignite Grant recognizes not only the promise of this specific project, but also Zhou’s broader expertise in understanding how T cells can be guided, supported, and strengthened to fight cancer more effectively. His research contributes to a growing wave of scientific innovation aimed at improving immunotherapy outcomes for patients with both blood cancers and, potentially, solid tumors — an area where current treatments face significant barriers. As immunotherapy continues to evolve, the work led by Gang Zhou stands as a compelling example of how foundational science, translational research, and clinical ambition can work together to push the field forward. To connect with Dr. Gang Zhou - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

3 min

MCG scientists investigate arthritis drug’s impact on Alzheimer’s disease

According to the Alzheimer’s Association, more than 7 million Americans are living with Alzheimer’s disease, and one in nine of those people is 65 or older. Although that number is expected to grow, researchers at the Medical College of Georgia at Augusta University are making progress on studies that could turn into life-saving treatments. Qin Wang, MD, PhD, professor in the Department of Neuroscience and Regenerative Medicine at MCG and Georgia Research Alliance Eminent Scholar in neuropharmacology, recently published a study titled “The PKCι‑β‑arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease,” in Molecular Degeneration, a leading journal in neurodegeneration. In the study, Wang and her team explored how certain proteins and enzymes interact in the brains of Alzheimer’s patients. Key players include the SORL1 gene, the PKCι enzyme and proteins SORLA, β‑arrestin2 and amyloid. SORL1 encodes SORLA, which helps regulate amyloid. Amyloid can form plaque in the brain, contributing to Alzheimer’s. People with the disease often have lower SORLA levels, which amplifies plaque production. “The goal is to increase SORLA levels in patients with AD. If we can boost it up, that would be great,” Wang said. “But if you want to know how to boost it up, you have to know how it is degraded, so that’s what our work is about – we’re trying to understand how its stability is regulated.” Wang’s research team found that PKCι can add a phosphate group to SORLA, which helps SORLA interact with β‑arrestin2. The PKCι‑β‑arrestin2 axis leads to SORLA degradation, reducing its levels and allowing amyloid plaques to grow unchecked, thereby worsening the disease condition. They discovered this by using biochemical methods and a mass spectrometer managed by Wenbo Zhi, PhD, at the Proteomics and Mass Spectrometry core lab at AU. “We conducted biochemical studies and found that SORLA can be phosphorylated. We identified the phosphorylation site and the interacting enzymes,” Wang explained. “Using the mass spectrometer with PKCι, we saw increased phosphorylation of SORLA at certain sites. Preventing that could stop SORLA degradation.” That’s where a rheumatoid arthritis drug called auranofin comes into play. “While it is an arthritis drug, it can also inhibit the PKCι enzyme,” Wang explained. The team conducted tests using Alzheimer’s mouse models and human iPS cells developed into neurons. For the mouse models, they treated the mice with auranofin for eight weeks, resulting in decreased amyloid levels, reduced neuroinflammation and improved cognitive function. Similar results were seen in human cells with increased SORLA levels and decreased amyloid levels. “A good thing about this is, because this is an FDA-approved drug, it’s ready to be tested in Alzheimer’s patients,” Wang said. “People often worry about drug safety because of long-term use in chronic diseases like Alzheimer’s, but, in this case, existing safety data for chronic use gives a good starting point for testing in Alzheimer’s patients. “I hope a drug company can pick that up for a trial with Alzheimer’s patients because we are trying to translate our bench work all the way to the bedside for treatment,” she continued. The study wraps up a five-year National Institute on Aging grant, a collaborative effort between Wang’s lab and the Kai Jiao, MD, PhD, lab in AU’s Center of Biotechnology and Genomic Medicine. Wang’s team is also working on other grant-funded Alzheimer’s-related projects and hopes to continue making advancements toward finding a cure for this debilitating disease. “All of our projects share the goal of finding a better treatment,” Wang said. “Related to this project in particular, we want to know how the SORLA protein works in different types of brain cells, given the brain’s complexity. Then we can determine how to specifically target that protein to develop more effective therapies.” Qin Wang, MD, PhD, researches the neuropharmacology and signaling mechanisms underlying neurological and psychiatric disorders. If you're interested in learning more about her work or booking an interview,  simply click on her icon now to arrange a time to talk.

2 min

Experts in the Media: CBD may help treat and reduce inflammation in Alzheimer's disease

In a recent Medical News Today article, Corrie Pelc reported on a study led by Babak Baban, PhD, in which inhaled CBD (cannabidiol) was tested in a mouse model of Alzheimer’s disease to examine its effects on neuroinflammation. Baban, associate dean for Research with AU's Dental College of Georgia and a professor with appointments in neurology and surgery in the Medical College of Georgia at Augusta University, explained that previous work from his group showed inhaled CBD to be more effective than oral or injected forms for certain neurological conditions, motivating them to explore its potential in Alzheimer’s research. He emphasized that Alzheimer’s is driven by multiple interacting biological processes – not just amyloid plaques – and sees inflammation as a promising new therapeutic target. In the study, inhaled CBD lowered activity in two major immune “alarm” pathways – IDO (indoleamine 2,3-dioxygenase) and cGAS-STING – both implicated in chronic inflammation. By dampening these pathways, CBD reduced levels of inflammatory cytokines and helped restore a more balanced immune environment in the brain. Baban framed this as a shift from symptom treatment to addressing underlying immune dysfunction, and noted that the findings could reorient how Alzheimer’s is approached. At the same time, he stressed that human trials are still needed: his team is preparing translational studies and holds an active Investigational New Drug (IND) application with the FDA for inhaled CBD in neuroinflammatory conditions, with Alzheimer’s disease as a natural next step. Read the full article here: Babak Baban, PhD, is a professor, immunologist and associate dean for research at the Dental College of Georgia at Augusta University where he has served for 13 of his 20 years as a translational and clinical immunologist. View his profile here Looking to know more about this important research or to connect with Babak Baban, PhD? He's available to speak with media – simply click on his icon to arrange an interview today.

View all posts